ReavillMED is a FDA 510K approved technology that provides a simple way to catheterize the human heart to ascertain patient condition. Once a peripheral IV cat
There are 750,000 Septic patients per year with a 35% mortality rate. Additionally, central line associated blood stream infections result in 30,000 to 62,000 deaths per year. The ReavillMED System is the key enabling element for Early Goal Directed Therapy to be started in the Emergency Department for the detection and treatment of sepsis. The ReavillMED System is self-contained and thus not exposed during insertion thereby reducing infection.